MMP-2 selectivity in hydroxamate-type inhibitors

Current Medicinal Chemistry

Volumn 19, Issue 7, 2012, Pages 1036-1064

  Serra, P ^a   Bruczko, M ^a,b   Zapico, J M ^a   Puckowska, A ^a,b   Garcia M A ^a   Martin Santamari S ^a   Ramos, A ^a   De Pascual Teresa, B ^a  

^a UNIVERSIDAD SAN PABLO CEU   (Spain)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Hydroxamate; Molecular modelling; Selective matrix metalloproteinase 2 inhibitors; Synthesis

Indexed keywords

A 070; A 071; A 072; A 076; A 077; A 078; A 079; A 080; A 081; A 083; A 084; A 085; A 086; A 087; A 088; A 089; A 090; ABT 518; ANTINEOPLASTIC AGENT; BATIMASTAT; CGS 27023A; DOXYCYCLINE; GELATINASE A; GELATINASE A INHIBITOR; HYDROXAMIC ACID DERIVATIVE; INCYCLINIDE; MATRIX METALLOPROTEINASE INHIBITOR; RO 323555; SC 44463; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CRYSTAL STRUCTURE; DRUG CLASSIFICATION; DRUG SELECTIVITY; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; IC 50; METAL BINDING; MOLECULAR MODEL; NONHUMAN; PROTEIN DOMAIN; PROTEIN SECONDARY STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 84858242083     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712799320628     Document Type: Review

References (138)

1. Cawston, T. E., Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol. Ther. 1996, 70, 163-182. (Pubitemid 26259574)
2. Johnson, L. L.; Dyer, R.; Hupe, D. J., Matrix metalloproteinases. Curr. Opin. Chem. Biol. 1998, 2, 466-471. (Pubitemid 128645699)
3. Massova, I.; Kotra, L. P.; Fridman, R.; Mobashery, S., Matrix metalloproteinases: structures, evolution, and diversification. FASEB J. 1998, 12, 1075-1095. (Pubitemid 28418938)
4. Scozzafava, A.; Supuran, C. T., Protease inhibitors: Synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties. J. Med. Chem. 2000, 43, 1858-1865. (Pubitemid 30305018)
5. Gersh, I.; Catchpole, H. R., The organization of ground substance and basement membrane and its significance in tissue injury disease and growth. Am. J. Anat. 1949, 85, 457-521, incl 457 pl.
6. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J., Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 1999, 99, 2735-2776.
7. Summers, J. B., In Annual Reports in Medicinal Chemistry, Robertson, D.; Plattner, J., Eds. Academic Press: San Diego, 1998; Vol. 33, pp 131-149.
8. Kessenbrock, K.; Plaks, V.; Werb, Z., Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141, 52-67.
9. Tuccinardi, T.; Martinelli, A.; Nuti, E.; Carelli, P.; Balzano, F.; Uccello- Barretta, G.; Murphy, G.; Rossello, A., Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3- methylbutanamides. Bioorg. Med. Chem. 2006, 14, 4260-4276.
10. Fingleton, B., Matrix Metalloproteinases as Valid Clinical Targets. Curr. Pharm. Des. 2007, 13, 333-346. (Pubitemid 46085282)
11. Vihinen, P.; Ala-aho, R.; Kahari, V.-M., Matrix Metalloproteinases as Therapeutic Targets in Cancer. Curr. Cancer Drug Targets 2005, 5, 203-220. (Pubitemid 40694861)
12. Sang, Q. X.; Jin, Y.; Newcomer, R. G.; Monroe, S. C.; Fang, X.; Hurst, D. R.; Lee, S.; Cao, Q.; Schwartz, M. A., Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Curr. Top. Med. Chem. 2006, 6, 289-316.
13. Dorman, G.; Cseh, S.; Hajdu, I.; Barna, L.; Konya, D.; Kupai, K.; Kovacs, L.; Ferdinandy, P., Matrix Metalloproteinase Inhibitors: A Critical Appraisal of Design Principles and Proposed Therapeutic Utility. Drugs 2010, 70, 949-964.
14. Gialeli, C.; Theocharis, A. D.; Karamanos, N. K., Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011, 278, 16-27.
15. Attolino, E.; Calderone, V.; Dragoni, E.; Fragai, M.; Richichi, B.; Luchinat, C.; Nativi, C., Structure-based approach to nanomolar, water soluble matrix metalloproteinases inhibitors (MMPIs). Eur. J. Med. Chem. 2010, 45, 5919-5925.
16. Calderone, V.; Fragai, M.; Luchinat, C.; Nativi, C.; Richichi, B.; Roelens, S., A High-Affinity Carbohydrate-Containing Inhibitor of Matrix Metalloproteinases. ChemMedChem 2006, 1, 598-601. (Pubitemid 44105785)
17. Wynn, R. L., Latest FDA approvals for dentistry. Gen. Dent. 1999, 47, 19-22.
18. Hu, J.; Van den Steen, P. E.; Sang, Q. X.; Opdenakker, G., Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 2007, 6, 480-498. (Pubitemid 47064570)
19. Overall, C. M.; Lopez-Otin, C., Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat. Rev. Cancer 2002, 2, 657-672. (Pubitemid 37328917)
20. Wilhelm, S. M.; Eisen, A. Z.; Teter, M.; Clark, S. D.; Kronberger, A.; Goldberg, G., Human fibroblast collagenase: glycosylation and tissue-specific levels of enzyme synthesis. Proc. Natl. Acad. Sci. U. S. A. 1986, 83, 3756-3760.
21. Hasty, K. A.; Pourmotabbed, T. F.; Goldberg, G. I.; Thompson, J. P.; Spinella, D. G.; Stevens, R. M.; Mainardi, C. L., Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases. J. Biol. Chem. 1990, 265, 11421-11424.
22. Collier, I. E.; Smith, J.; Kronberger, A.; Bauer, E. A.; Wilhelm, S. M.; Eisen, A. Z.; Goldberg, G. I., The structure of the human skin fibroblast collagenase gene. J. Biol. Chem. 1988, 263, 10711-10713.
23. Wilhelm, S. M.; Collier, I. E.; Kronberger, A.; Eisen, A. Z.; Marmer, B. L.; Grant, G. A.; Bauer, E. A.; Goldberg, G. I., Human skin fibroblast stromelysin: structure, glycosylation, substrate specificity, and differential expression in normal and tumorigenic cells. Proc. Natl. Acad. Sci. U. S. A. 1987, 84, 6725-6729. (Pubitemid 18025491)
24. Liotta, L. A.; Tryggvason, K.; Garbisa, S.; Robey, P. G.; Abe, S., Partial purification and characterization of a neutral protease which cleaves type IV collagen. Biochemistry 1981, 20, 100-104.
25. Senior, R. M.; Griffin, G. L.; Fliszar, C. J.; Shapiro, S. D.; Goldberg, G. I.; Welgus, H. G., Human 92- and 72-kilodalton type IV collagenases are elastases. J. Biol. Chem. 1991, 266, 7870-7875. (Pubitemid 21906446)
26. Aimes, R. T.; Quigley, J. P., Matrix Metalloproteinase-2 Is an Interstitial Collagenase. J. Biol. Chem. 1995, 270, 5872-5876.
27. Gioia, M.; Monaco, S.; Fasciglione, G. F.; Coletti, A.; Modesti, A.; Marini, S.; Coletta, M., Characterization of the Mechanisms by which Gelatinase A, Neutrophil Collagenase, and Membrane-Type Metalloproteinase MMP-14 Recognize Collagen I and Enzymatically Process the Two α-Chains. J. Mol. Biol. 2007, 368, 1101-1113. (Pubitemid 46574666)
28. Muller, D.; Quantin, B.; Gesnel, M. C.; Millon-Collard, R.; Abecassis, J.; Breathnach, R., The collagenase gene family in humans consists of at least four members. Biochem. J. 1988, 253, 187-192.
29. Clark, H. F.; Gurney, A. L.; Abaya, E.; Baker, K.; Baldwin, D.; Brush, J.; Chen, J.; Chow, B.; Chui, C.; Crowley, C.; Currell, B.; Deuel, B.; Dowd, P.; Eaton, D.; Foster, J.; Grimaldi, C.; Gu, Q.; Hass, P. E.; Heldens, S.; Huang, A.; Kim, H. S.; Klimowski, L.; Jin, Y.; Johnson, S.; Lee, J.; Lewis, L.; Liao, D.; Mark, M.; Robbie, E.; Sanchez, C.; Schoenfeld, J.; Seshagiri, S.; Simmons, L.; Singh, J.; Smith, V.; Stinson, J.; Vagts, A.; Vandlen, R.; Watanabe, C.; Wieand, D.; Woods, K.; Xie, M. H.; Yansura, D.; Yi, S.; Yu, G.; Yuan, J.; Zhang, M.; Zhang, Z.; Goddard, A.; Wood, W. I.; Godowski, P.; Gray, A., The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003, 13, 2265-2270.
30. Basset, P.; Bellocq, J. P.; Wolf, C.; Stoll, I.; Hutin, P.; Limacher, J. M.; Podhajcer, O. L.; Chenard, M. P.; Rio, M. C.; Chambon, P., A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990, 348, 699-704. (Pubitemid 120015135)
31. Pei, D.; Majmudar, G.; Weiss, S. J., Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J. Biol. Chem. 1994, 269, 25849-25855. (Pubitemid 24336285)
32. Owen, C. A.; Hu, Z.; Lopez-Otin, C.; Shapiro, S. D., Membrane-bound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpinase. J. Immunol. 2004, 172, 7791-7803. (Pubitemid 38747647)
33. Van den Steen, P. E.; Opdenakker, G.; Wormald, M. R.; Dwek, R. A.; Rudd, P. M., Matrix remodelling enzymes, the protease cascade and glycosylation. Biochim. Biophys. Acta 2001, 1528, 61-73. (Pubitemid 33001266)
34. Quantin, B.; Murphy, G.; Breathnach, R., Pump-1 cDNA codes for a protein with characteristics similar to those of classical collagenase family members. Biochemistry 1989, 28, 5327-5334. (Pubitemid 19175740)
35. Park, H. I.; Ni, J.; Gerkema, F. E.; Liu, D.; Belozerov, V. E.; Sang, Q. X., Identification and characterization of human endometase (Matrix metalloproteinase-26) from endometrial tumor. J. Biol. Chem. 2000, 275, 20540-20544.
36. Shapiro, S. D.; Kobayashi, D. K.; Ley, T. J., Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J. Biol. Chem. 1993, 268, 23824-23829. (Pubitemid 23335353)
37. Chandler, S.; Cossins, J.; Lury, J.; Wells, G., Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alpha fusion protein. Biochem. Biophys. Res. Commun. 1996, 228, 421-429. (Pubitemid 26396090)
38. Sato, H.; Takino, T.; Okada, Y.; Cao, J.; Shinagawa, A.; Yamamoto, E.; Seiki, M., A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370, 61-65. (Pubitemid 24216953)
39. Will, H.; Hinzmann, B., cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur. J. Biochem. 1995, 231, 602-608.
40. Takino, T.; Sato, H.; Shinagawa, A.; Seiki, M., Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. J. Biol. Chem. 1995, 270, 23013-23020.
41. Puente, X. S.; Pendas, A. M.; Llano, E.; Velasco, G.; Lopez-Otin, C., Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res. 1996, 56, 944-949. (Pubitemid 26065382)
42. Llano, E.; Pendas, A. M.; Freije, J. P.; Nakano, A.; Knauper, V.; Murphy, G.; Lopez-Otin, C., Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. Cancer Res. 1999, 59, 2570-2576. (Pubitemid 29269100)
43. Velasco, G.; Cal, S.; Merlos-Suarez, A.; Ferrando, A. A.; Alvarez, S.; Nakano, A.; Arribas, J.; Lopez-Otin, C., Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. Cancer Res. 2000, 60, 877-882. (Pubitemid 30129519)
44. Strongin, A. Y.; Collier, I.; Bannikov, G.; Marmer, B. L.; Grant, G. A.; Goldberg, G. I., Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 1995, 270, 5331-5338.
45. Ohuchi, E.; Imai, K.; Fujii, Y.; Sato, H.; Seiki, M.; Okada, Y., Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J. Biol. Chem. 1997, 272, 2446-2451. (Pubitemid 27058534)
46. Takino, T.; Koshikawa, N.; Miyamori, H.; Tanaka, M.; Sasaki, T.; Okada, Y.; Seiki, M.; Sato, H., Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases. Oncogene 2003, 22, 4617-4626. (Pubitemid 36976435)
47. Stracke, J. O.; Hutton, M.; Stewart, M.; Pendas, A. M.; Smith, B.; Lopez- Otin, C.; Murphy, G.; Knauper, V., Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme. J. Biol. Chem. 2000, 275, 14809-14816.
48. Marchenko, G. N.; Marchenko, N. D.; Strongin, A. Y., The structure and regulation of the human and mouse matrix metalloproteinase-21 gene and protein. Biochem. J. 2003, 372, 503-515. (Pubitemid 36723896)
49. Ohnishi, J.; Ohnishi, E.; Jin, M.; Hirano, W.; Nakane, D.; Matsui, H.; Kimura, A.; Sawa, H.; Nakayama, K.; Shibuya, H.; Nagashima, K.;Takahashi, T., Cloning and characterization of a rat ortholog of MMP-23 (matrix metalloproteinase-23), a unique type of membrane-anchored matrix metalloproteinase and conditioned switching of its expression during the ovarian follicular development. Mol. Endocrinol. 2001, 15, 747-764. (Pubitemid 32411314)
50. Lohi, J.; Wilson, C. L.; Roby, J. D.; Parks, W. C., Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J. Biol. Chem. 2001, 276, 10134-10144.
51. Gomis-Ruth, F. X.; Maskos, K.; Betz, M.; Bergner, A.; Huber, R.; Suzuki, K.; Yoshida, N.; Nagase, H.; Brew, K.; Bourenkov, G. P.; Bartunik, H.; Bode, W., Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 1997, 389, 77-81. (Pubitemid 27387694)
52. Murphy, G.; Nguyen, Q.; Cockett, M. I.; Atkinson, S. J.; Allan, J. A.; Knight, C. G.; Willenbrock, F.; Docherty, A. J., Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J. Biol. Chem. 1994, 269, 6632-6636. (Pubitemid 24191045)
53. Lovejoy, B.; Cleasby, A.; Hassell, A. M.; Longley, K.; Luther, M. A.; Weigl, D.; McGeehan, G.; McElroy, A. B.; Drewry, D.; Lambert, M. H.; et al., Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science 1994, 263, 375-377.
54. Borkakoti, N.; Winkler, F. K.; Williams, D. H.; D'Arcy, A.; Broadhurst, M. J.; Brown, P. A.; Johnson, W. H.; Murray, E. J., Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Nat. Struct. Biol. 1994, 1, 106-110. (Pubitemid 24974823)
55. Lovejoy, B.; Hassell, A. M.; Luther, M. A.; Weigl, D.; Jordan, S. R., Crystal structures of recombinant 19-kDa human fibroblast collagenase complexed to itself. Biochemistry 1994, 33, 8207-8217. (Pubitemid 24241053)
56. Spurlino, J. C.; Smallwood, A. M.; Carlton, D. D.; Banks, T. M.; Vavra, K. J.; Johnson, J. S.; Cook, E. R.; Falvo, J.; Wahl, R. C.; Pulvino, T. A.; et al., 1.56 A structure of mature truncated human fibroblast collagenase. Proteins 1994, 19, 98-109.
57. Bode, W.; Reinemer, P.; Huber, R.; Kleine, T.; Schnierer, S.; Tschesche, H., The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J. 1994, 13, 1263-1269. (Pubitemid 24090206)
58. Stams, T.; Spurlino, J. C.; Smith, D. L.; Wahl, R. C.; Ho, T. F.; Qoronfleh, M. W.; Banks, T. M.; Rubin, B., Structure of human neutrophil collagenase reveals large S1' specificity pocket. Nat. Struct. Biol. 1994, 1, 119-123. (Pubitemid 24974825)
59. Grams, F.; Crimmin, M.; Hinnes, L.; Huxley, P.; Pieper, M.; Tschesche, H.; Bode, W., Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. Biochemistry 1995, 34, 14012-14020.
60. Grams, F.; Reinemer, P.; Powers, J. C.; Kleine, T.; Pieper, M.; Tschesche, H.; Huber, R.; Bode, W., X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design. Eur. J. Biochem. 1995, 228, 830-841.
61. Gooley, P. R.; O'Connell, J. F.; Marcy, A. I.; Cuca, G. C.; Salowe, S. P.; Bush, B. L.; Hermes, J. D.; Esser, C. K.; Hagmann, W. K.; Springer, J. P.; et al., The NMR structure of the inhibited catalytic domain of human stromelysin-1. Nat. Struct. Biol. 1994, 1, 111-118.
62. Van Doren, S. R.; Kurochkin, A. V.; Hu, W.; Ye, Q. Z.; Johnson, L. L.; Hupe, D. J.; Zuiderweg, E. R., Solution structure of the catalytic domain of human stromelysin complexed with a hydrophobic inhibitor. Protein Sci. 1995, 4, 2487-2498.
63. Becker, J. W.; Marcy, A. I.; Rokosz, L. L.; Axel, M. G.; Burbaum, J. J.; Fitzgerald, P. M.; Cameron, P. M.; Esser, C. K.; Hagmann, W. K.; Hermes, J. D.; et al., Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme. Protein Sci. 1995, 4, 1966-1976.
64. Browner, M. F.; Smith, W. W.; Castelhano, A. L., Matrilysin-inhibitor complexes: common themes among metalloproteases. Biochemistry 1995, 34, 6602-6610.
65. Bertini, I.; Calderone, V.; Cosenza, M.; Fragai, M.; Lee, Y.; Luchinat, C.; Mangani, S.; Terni, B.; Turano, P., Conformational variability of matrix metalloproteinases: Beyond a single 3D structure. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 5334-5339. (Pubitemid 40530258)
66. Massova, I.; Kotra, L. P.; Mobashery, S., Structural insight into the binding motifs for the calcium ion and the non-catalytic zinc in matrix metalloproteases. Bioorg. Med. Chem. Lett. 1998, 8, 853-858. (Pubitemid 28160053)
67. Upadhye, S.; Ananthanarayanan, V. S., Interaction of peptide substrates of fibroblast collagenase with divalent cations: Ca2+ binding by substrate as a suggested recognition signal for collagenase action. Biochem. Biophys. Res. Commun. 1995, 215, 474-482.
68. Morgunova, E.; Tuuttila, A.; Bergmann, U.; Isupov, M.; Lindqvist, Y.; Schneider, G.; Tryggvason, K., Structure of human pro-matrix metalloproteinase-2: Activation mechanism revealed. Science 1999, 284, 1667-1670. (Pubitemid 29291376)
69. Fernandez-Catalan, C.; Bode, W.; Huber, R.; Turk, D.; Calvete, J. J.; Lichte, A.; Tschesche, H.; Maskos, K., Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO J. 1998, 17, 5238-5248. (Pubitemid 28408489)
70. Harrison, R. K.; Chang, B.; Niedzwiecki, L.; Stein, R. L., Mechanistic studies on the human matrix metalloproteinase stromelysin. Biochemistry 1992, 31, 10757-10762.
71. Díaz, N.; Suárez, D., Peptide Hydrolysis Catalyzed by Matrix Metalloproteinase 2: A Computational Study. J. Phys. Chem. 2008, 112, 8412-8424.
72. Babine, R. E.; Bender, S. L., Molecular Recognition of Protein-Ligand Complexes: Applications to Drug Design. Chem. Rev. 1997, 97, 1359-1472. (Pubitemid 127659602)
73. Tallant, C.; Marrero, A.; Gomis-Ruth, F. X., Matrix metalloproteinases: Fold and function of their catalytic domains. Biochim. Biophys. Acta 2010, 1803, 20-28.
74. Gross, J.; Harper, E.; Harris, E. D.; McCroskery, P. A.; Highberger, J. H.; Corbett, C.; Kang, A. H., Animal collagenases: specificity of action, and structures of the substrate cleavage site. Biochem. Biophys. Res. Commun. 1974, 61, 605-612.
75. Netzel-Arnett, S.; Fields, G.; Birkedal-Hansen, H.; E, V. W., Sequence Specificities of Human Fibroblast and Neutrophil Collagenases. J. Biol. Chem. 1991, 266, 6747-6755.
76. Terp, G. E.; Christensen, I. T.; Jorgensen, F. S., Structural differences of matrix metalloproteinases. Homology modeling and energy minimization of enzyme-substrate complexes. J. Biomol. Struct. Dyn. 2000, 17, 933-946. (Pubitemid 30480359)
77. Bode, W.; Fernandez-Catalan, C.; Tschesche, H.; Grams, F.; Nagase, H.; Maskos, K., Structural properties of matrix metalloproteinases. Cell. Mol. Life Sci. 1999, 55, 639-652. (Pubitemid 29221596)
78. Natchus, M. G.; Bookland, R. G.; De, B.; Almstead, N. G.; Pikul, S.; Janusz, M. J.; Heitmeyer, S. A.; Hookfin, E. B.; Hsieh, L. C.; Dowty, M. E.; Dietsch, C. R.; Patel, V. S.; Garver, S. M.; Gu, F.; Pokross, M. E.; Mieling, G. E.; Baker, T. R.; Foltz, D. J.; Peng, S. X.; Bornes, D. M.; Strojnowski, M. J.; Taiwo, Y. O., Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines. J. Med. Chem. 2000, 43, 4948-4963. (Pubitemid 32039016)
79. Almstead, N. G.; Bradley, R. S.; Pikul, S.; De, B.; Natchus, M. G.; Taiwo, Y. O.; Gu, F.; Williams, L. E.; Hynd, B. A.; Janusz, M. J.; Dunaway, C. M.; Mieling, G. E., Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. J. Med. Chem. 1999, 42, 4547-4562. (Pubitemid 29530009)
80. Pikul, S.; McDow Dunham, K. L.; Almstead, N. G.; De, B.; Natchus, M. G.; Anastasio, M. V.; McPhail, S. J.; Snider, C. E.; Taiwo, Y. O.; Rydel, T.; Dunaway, C. M.; Gu, F.; Mieling, G. E., Discovery of potent, achiral matrix metalloproteinase inhibitors. J. Med. Chem. 1998, 41, 3568-3571. (Pubitemid 28449339)
81. Hanessian, S.; Moitessier, N.; Gauchet, C.; Viau, M., N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets. J. Med. Chem. 2001, 44, 3066-3073. (Pubitemid 32862337)
82. Reiter, L. A.; Mitchell, P. G.; Martinelli, G. J.; Lopresti-Morrow, L. L.; Yocum, S. A.; Eskra, J. D., Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3. Bioorg. Med. Chem. Lett. 2003, 13, 2331-2336. (Pubitemid 36724976)
83. Welch, A. R.; Holman, C. M.; Huber, M.; Brenner, M. C.; Browner, M. F.; Van Wart, H. E., Understanding the P1' specificity of the matrix metalloproteinases: effect of S1' pocket mutations in matrilysin and stromelysin-1. Biochemistry 1996, 35, 10103-10109. (Pubitemid 26269926)
84. Matter, H.; Schwab, W., Affinity and selectivity of matrix metalloproteinase inhibitors: a chemometrical study from the perspective of ligands and proteins. J. Med. Chem. 1999, 42, 4506-4523. (Pubitemid 29530006)
85. Terp, G. E.; Cruciani, G.; Christensen, I. T.; Jorgensen, F. S., Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. J. Med. Chem. 2002, 45, 2675-2684. (Pubitemid 34627640)
86. Pirard, B.; Matter, H., Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis. J. Med. Chem. 2006, 49, 51-69. (Pubitemid 43077322)
87. McCoy, M. A.; Dellwo, M. J.; Schneider, D. M.; Banks, T. M.; Falvo, J.; Vavra, K. J.; Mathiowetz, A. M.; Qoronfleh, M. W.; Ciccarelli, R.; Cook, E. R.; Pulvino, T. A.; Wahl, R. C.; Wang, H., Assignments and structure determination of the catalytic domain of human fibroblast collagenase using 3D double and triple resonance NMR spectroscopy. J. Biomol. NMR 1997, 9, 11-24.
88. Rockwell, A.; Melden, M.; Copeland, R. A.; Hardman, K.; Decicco, C. P.; DeGrado, W. F., Complementarity of Combinatorial Chemistry and Structure-Based Ligand Design: Application to the Discovery of Novel Inhibitors of Matrix Metalloproteinases. J. Am. Chem. Soc. 1996, 118, 10337-10338. (Pubitemid 26375234)
89. Finzel, B. C.; Baldwin, E. T.; Bryant, G. L., Jr.; Hess, G. F.; Wilks, J. W.; Trepod, C. M.; Mott, J. E.; Marshall, V. P.; Petzold, G. L.; Poorman, R. A.; O'Sullivan, T. J.; Schostarez, H. J.; Mitchell, M. A., Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity. Protein Sci. 1998, 7, 2118-2126. (Pubitemid 28495798)
90. Stockman, B. J.; Waldon, D. J.; Gates, J. A.; Scahill, T. A.; Kloosterman, D. A.; Mizsak, S. A.; Jacobsen, E. J.; Belonga, K. L.; Mitchell, M. A.; Mao, B.; Petke, J. D.; Goodman, L.; Powers, E. A.; Ledbetter, S. R.; Kaytes, P. S.; Vogeli, G.; Marshall, V. P.; Petzold, G. L.; Poorman, R. A., Solution structures of stromelysin complexed to thiadiazole inhibitors. Protein Sci. 1998, 7, 2281-2286. (Pubitemid 28506944)
91. Nicolotti, O.; Miscioscia, T. F.; Leonetti, F.; Muncipinto, G.; Carotti, A., Screening of matrix metalloproteinases available from the protein data bank: Insights into biological functions, domain organization, and zinc binding groups. J. Chem. Inf. Model. 2007, 47, 2439-2448.
92. Overall, C. M.; Kleifeld, O., Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer 2006, 94, 941-946.
93. Bertini, I.; Calderone, V.; Fragai, M.; Giachetti, A.; Loconte, M.; Luchinat, C.; Maletta, M.; Nativi, C.; Yeo, K. J., Exploring the subtleties of drugreceptor interactions: the case of matrix metalloproteinases. J. Am. Chem. Soc. 2007, 129, 2466-2475. (Pubitemid 46364051)
94. Saghatelian, A.; Jessani, N.; Joseph, A.; Humphrey, M.; Cravatt, B. F., Activity-based probes for the proteomic profiling of metalloproteases. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 10000-10005. (Pubitemid 38891185)
95. Yadav, R. K.; Gupta, S. P.; Sharma, P. K.; Patil, V. M., Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: a review. Curr. Med. Chem. 2011, 18, 1704-1722.
96. Johnson, W. H.; Roberts, N. A.; Borkakoti, N., Collagenase inhibitors: their design and potential therapeutic use. J. Enzym. Inhib. 1987, 2, 1-22. (Pubitemid 17157138)
97. Broadhurst, M. J.; Brown, P. A.; Lawton, G.; Ballantyne, N.; Borkakoti, N.; Bottomley, K. M.; Cooper, M. I.; Eatherton, A. J.; Kilford, I. R.; Malsher, P. J.; Nixon, J. S.; Lewis, E. J.; Sutton, B. M.; Johnson, W. H., Design and synthesis of the cartilage protective agent (CPA, Ro32-3555). Bioorg. Med. Chem. Lett. 1997, 7, 2299-2302. (Pubitemid 27387433)
98. Bottomley, K. M.; Johnson, W. H.; Walter, D. S., Matrix metalloproteinase inhibitors in arthritis. J. Enzym. Inhib. 1998, 13, 79-101. (Pubitemid 28230676)
99. MacPherson, L. J.; Bayburt, E. K.; Capparelli, M. P.; Carroll, B. J.; Goldstein, R.; Justice, M. R.; Zhu, L.; Hu, S.; Melton, R. A.; Fryer, L.; Goldberg, R. L.; Doughty, J. R.; Spirito, S.; Blancuzzi, V.; Wilson, D.; O'Byrne, E. M.; Ganu, V.; Parker, D. T., Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. 1997, 40, 2525-2532. (Pubitemid 27347016)
100. Wada, C. K.; Holms, J. H.; Curtin, M. L.; Dai, Y.; Florjancic, A. S.; Garland, R. B.; Guo, Y.; Heyman, H. R.; Stacey, J. R.; Steinman, D. H.; Albert, D. H.; Bouska, J. J.; Elmore, I. N.; Goodfellow, C. L.; Marcotte, P. A.; Tapang, P.; Morgan, D. W.; Michaelides, M. R.; Davidsen, S. K., Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. J. Med. Chem. 2002, 45, 219-232. (Pubitemid 34038556)
101. Hajduk, P. J.; Shuker, S. B.; Nettesheim, D. G.; Craig, R.; Augeri, D. J.; Betebenner, D.; Albert, D. H.; Guo, Y.; Meadows, R. P.; Xu, L.; Michaelides, M.; Davidsen, S. K.; Fesik, S. W., NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability. J. Med. Chem. 2002, 45, 5628-5639. (Pubitemid 35453755)
102. Skiles, J. W.; Gonnella, N. C.; Jeng, A. Y., The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem. 2001, 8, 425-474. (Pubitemid 32409788)
103. O'Brien, P. M.; Ortwine, D. F.; Pavlovsky, A. G.; Picard, J. A.; Sliskovic, D. R.; Roth, B. D.; Dyer, R. D.; Johnson, L. L.; Man, C.; Hallak, H., Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J. Med. Chem. 2000, 43, 156-166. (Pubitemid 30078147)
104. Rao, B. G., Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. Curr. Pharm. Des. 2005, 11, 295-322. (Pubitemid 40277859)
105. Engel, C. K.; Pirard, B.; Schimanski, S.; Kirsch, R.; Habermann, J.; Klingler, O.; Schlotte, V.; Weithmann, K. U.; Wendt, K. U., Structural basis for the highly selective inhibition of MMP-13. Chem. Biol. 2005, 12, 181-189. (Pubitemid 40281325)
106. Amadasi, A.; Cozzini, P.; Incerti, M.; Duce, E.; Fisicaro, E.; Vicini, P., Molecular modeling of binding between amidinobenzisothiazoles, with antidegenerative activity on cartilage, and matrix metalloproteinase-3. Bioorg. Med. Chem. 2007, 15, 1420-1429. (Pubitemid 46038127)
107. Konstantinopoulos, P. A.; Karamouzis, M. V.; Papatsoris, A. G.; Papavassiliou, A. G., Matrix metalloproteinase inhibitors as anticancer agents. Int. J. Biochem. Cell. Biol. 2008, 40, 1156-1168.
108. Feng, Y. Q.; Likos, J. J.; Zhu, L. M.; Woodward, H.; Munie, G.; McDonald, J. J.; Stevens, A. M.; Howard, C. P.; De Crescenzo, G. A.; Welsch, D.; Shieh, H. S.; Stallings, W. C., Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor. Biochim. Biophys. Acta 2002, 1598, 10-23.
109. Groves, M. D.; Puduvalli, V. K.; Hess, K. R.; Jaeckle, K. A.; Peterson, P.; Yung, W. K. A.; Levin, V. A., Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol. 2002, 20, 1383-1388. (Pubitemid 34177446)
110. Levy, D. E.; Lapierre, F.; Liang, W.; Ye, W.; Lange, C. W.; Li, X.; Grobelny, D.; Casabonne, M.; Tyrrell, D.; Holme, K.; Nadzan, A.; Galardy, R. E., Matrix metalloproteinase inhibitors: a structure-activity study. J. Med. Chem. 1998, 41, 199-223. (Pubitemid 28114362)
111. Moroy, G.; Denhez, C.; El Mourabit, H.; Toribio, A.; Dassonville, A.; Decarme, M.; Renault, J. H.; Mirand, C.; Bellon, G.; Sapi, J.; Alix, A. J. P.; Hornebeck, W.; Bourguet, E., Simultaneous presence of unsaturation and long alkyl chain at P'(1) of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies. Bioorg. Med. Chem. 2007, 15, 4753-4766. (Pubitemid 46844885)
112. Becker, D. P.; Villamil, C. I.; Barta, T. E.; Bedell, L. J.; Boehm, T. L.; DeCrescenzo, G. A.; Freskos, J. N.; Getman, D. P.; Hockerman, S.; Heintz, R.; Howard, S. C.; Li, L. H.; McDonald, J. J.; Carron, C. p.; Funckes-Shippy, C. L.; Mehta, P. P.; Munie, G. E.; Swearingen, C. A., Synthesis and Structure-Activity Relationships of β- and α-Piperidine Sulfone Hydroxamic Acid Matrix Metalloproteinase Inhibitors With Oral Antitumor Efficacy. J. Med. Chem. 2005, 48, 6713-6730. (Pubitemid 41504727)
113. Zapico, J. M.; Serra, P.; García-Sanmartín, J.; Filipiak, K.; Carbajo, R. J.; Schott, A. K.; Pineda-Lucena, A.; Martínez, A.; Martín-Santamaría, S.; de Pascual-Teresa, B.; Ramos, A., Potent and Selective "Clicked" MMP2 Inhibitors: Synthesis, Molecular Modeling and Biological Exploration. Org. Biomol. Chem. 2011, 9, 4587-4599.
114. Cherney, R. J.; King, B. W.; Gilmore, J. L.; Liu, R. Q.; Covington, M. B.; Duan, J. J.; Decicco, C. P., Conversion of potent MMP inhibitors into selective TACE inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 1028-1031. (Pubitemid 43059872)
115. Cherney, R. J.; Mo, R. W.; Meyer, D. T.; Hardman, K. D.; Liu, R. Q.; Covington, M. B.; Qian, M. X.; Wasserman, Z. R.; Christ, D. D.; Trzaskos, J. M.; Newton, R. C.; Decicco, C. P., Sultam hydroxamates as novel matrix metalloproteinase inhibitors. J. Med. Chem. 2004, 47, 2981-2983. (Pubitemid 38702695)
116. Supuran, C. T.; Casini, A.; Scozzafava, A., Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents. Med. Res. Rev. 2003, 23, 535-558. (Pubitemid 37034144)
117. Cheng, X. C.; Wang, Q.; Fang, H.; Xu, W. F., Role of sulfonamide group in matrix metalloproteinase inhibitors. Curr. Med. Chem. 2008, 15, 368-373.
118. Kiyama, R.; Tamura, Y.; Watanabe, F.; Tsuzuki, H.; Ohtani, M.; Yodo, M., Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. J. Med. Chem. 1999, 42, 1723-1738. (Pubitemid 29244966)
119. Scozzafava, A.; Supuran, C. T., Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J. Med. Chem. 2000, 43, 3677-3687.
120. Nuti, E.; Orlandini, E.; Nencetti, S.; Rossello, A.; Innocenti, A.; Scozzafava, A.; Supuran, C. T., Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates. Bioorg. Med. Chem. 2007, 15, 2298-2311. (Pubitemid 46242198)
121. Wagner, S.; Breyholz, H. J.; Law, M. P.; Faust, A.; Holtke, C.; Schroer, S.; Haufe, G.; Levkau, B.; Schober, O.; Schafers, M.; Kopka, K., Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-Hydroxy- 2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl- butanamide as potential tools for the molecular Imaging of activated MMPs with PET. J. Med. Chem. 2007, 50, 5752-5764. (Pubitemid 350106030)
122. Duan, J. J.; Chen, L.; Wasserman, Z. R.; Lu, Z.; Liu, R. Q.; Covington, M. B.; Qian, M.; Hardman, K. D.; Magolda, R. L.; Newton, R. C.; Christ, D. D.; Wexler, R. R.; Decicco, C. P., Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships. J. Med. Chem. 2002, 45, 4954-4957. (Pubitemid 35278690)
123. Cherney, R. J.; Duan, J. J.; Voss, M. E.; Chen, L.; Wang, L.; Meyer, D. T.; Wasserman, Z. R.; Hardman, K. D.; Liu, R. Q.; Covington, M. B.; Qian, M.; Mandlekar, S.; Christ, D. D.; Trzaskos, J. M.; Newton, R. C.; Magolda, R. L.; Wexler, R. R.; Decicco, C. P., Design, synthesis, and evaluation of
124. Yang, S.-M.; Scannevin, R. H.; Bingbing, W.; Burke, S. L.; Wilson, L. J.; Karnachi, P.; Rhodes, K. J.; Lagu, B.; Murray, W. V., b-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: Part 1. Design, synthesis, and lead identification. Bioorg. Med. Chem. Lett. 2008, 18, 1135-1139 (Pubitemid 351179319)
125. Yang, S.-M.; Scannevin, R. H.; Wang, B.; Burke, S. L.; Huang, Z.; Karnachi, P.; Wilson, L. J.; Rhodes, K. J.; Lagu, B.; Murray, W. V., b-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: Part 2. Optimization of a-amino substituents. Bioorg. Med. Chem. Lett. 2008, 18, 1140-1145 (Pubitemid 351179328)
126. Takahashi, K.; Ikura, M.; Habashita, H.; Nishizaki, M.; Sugiura, T.; Yamamoto, S.; Nakatani, S.; Ogawa, K.; Ohno, H.; Nakai, H.; Toda, M., Novel matrix metalloproteinase inhibitors: Generation of lead compounds by the in silico fragment-based approach. Bioorg. Med. Chem. 2005, 13, 4527-4543. (Pubitemid 40813241)
127. Nakatani, S.; Ikura, M.; Yamamoto, S.; Nishita, Y.; Itadani, S.; Habashita, H.; Sugiura, T.; Ogawa, K.; Ohno, H.; Takahashi, K.; Nakai, H.; Toda, M., Design and synthesis of novel metalloproteinase inhibitors. Bioorg. Med. Chem. 2006, 14, 5402-5422. (Pubitemid 43903243)
128. Yamamoto, S.; Nakatani, S.; Ikura, M.; Sugiura, T.; Nishita, Y.; Itadani, S.; Ogawa, K.; Ohno, H.; Takahashi, K.; Nakai, H.; Toda, M., Design and synthesis of an orally active matrix metalloproteinase inhibitor. Bioorg. Med. Chem. 2006, 14, 6383-6403. (Pubitemid 44224071)
129. Santos, M. A.; Marques, S. M.; Tuccinardi, T.; Carelli, P.; Panelli, L.; Rossello, A., Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors. Bioorg. Med. Chem. 2006, 14, 7539-7550. (Pubitemid 44486794)
130. Marques, S. M.; Nuti, E.; Rossello, A.; Supura, C. T.; Tuccinardi, T.; Martinelli, A.; Santos, M. A., Dual Inhibitors of Matrix Metalloproteinases and Carbonic Anhydrases: Iminodiacetyl-Based Hydroxamate- Benzenesulfonamide Conjugates. J. Med. Chem. 2008, 51, 7968-7979.
131. Marques, S. M.; Chaves, S.; Rossello, A.; Tuccinardi, T.; Santos, M. A., Iminodiacetyl-monohydroxamate derivatives as potent and selective MMP inhibitors. Metal Ions Biol. Med. 2006, 9, 117-121.
132. Xi, L.; Du, J.; Li, S.; Li, J.; Liu, H.; Yao, X., A combined molecular modeling study on gelatinases and their potent inhibitors. J. Comp. Chem. 2009, 31, 24-42.
133. Isaksson, J.; Nystrom, S.; Derbyshire, D.; Wallberg, H.; Agback, T.; Kovacs, H.; Bertini, I.; Giachetti, A.; Luchinat, C., Does a fast nuclear magnetic resonance spectroscopy- and X-ray crystallography hybrid approach provide reliable structural information of ligand-protein complexes? A case study of metalloproteinases. J. Med. Chem. 2009, 52, 1712-1722.
134. Díaz, N.; Suárez, D.; Suárez, E., Kinetic and binding effects in peptide substrate selectivity of matrix metalloproteinase-2: Molecular dynamics and QM/MM calculations. Proteins 2010, 78, 1-11.
135. Díaz, N.; Suárez, D., Molecular Dynamics Simulations of Matrix Metalloproteinase 2: Role of the Structural Metal Ions. Biochemistry 2007, 46, 8943-8952. (Pubitemid 47237369)
136. Díaz, N.; Suárez, D., Molecular dynamics simulations of the active matrix metalloproteinase-2: Positioning of the N-terminal fragment and binding of a small peptide substrate. Proteins: Structure, Function, and Bioinformatics 2008, 72, 50-61. (Pubitemid 351809147)
137. Díaz, N.; Suárez, D.; Sordo, T. L., Quantum Chemical Study on the Coordination Environment of the Catalytic Zinc ion in Matrix Metalloproteinases. J. Phys. Chem. B 2006, 110, 24222-24230. (Pubitemid 46065863)
138. Giangreco, I.; Nicolotti, O.; Carotti, A.; De Carlo, F.; Gargano, G.; Bellotti, R., Analysis of X-ray Structures of Matrix Metalloproteinases via Chaotic Map Clustering. BMC Bioinformatics 2010, 11, 1-13.